API | amonafide

amonafide Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Amonafide was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator. ^Wikipedia

Chemistry

SMILES: CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23
InChIKey: UPALIKSFLSVKIS-UHFFFAOYSA-N
Mol. Mass: 283.33
ALogP: 1.58 Partition coefficient
ChEMBL Molecule:
amonafide

More Chemistry

Pharmacology

Mechanism of Action:
- DNA topoisomerase 1 (Homo sapiens) ^UniProt
- DNA topoisomerase 2-alpha (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

1h-benz(de)isoquinoline-1,3(2h)-dione, 5-amino-2-(2-(dimethylamino)ethyl)- | 5-amino-2-(2-dimethylaminoethyl)benzo(de)isoquinolin-1,3-dione | amonafide | amonafide l-malate | as-1413 | benzisoquinolinedione | fa 142 | m-fa 142 | m-fa-142 | mfa 142 | mfa-142 | nafidimide | nsc 308847 | nsc-308847

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Leukemia, Myeloid, Acute (Phase 3)

Prostatic Neoplasms (Phase 1/Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue